Materials and methods for suppressing and/or treating bone related diseases and symptoms
Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.
1. A compound, comprising:
A-Y—B,
wherein:
A is
and X is selected from the group consisting of: H and
Y is a linker of formula NR 1 ;
R′ is H, CH 3 , alkyl, halogen, CF 3 , CN, OH, OCH 3 , or O-alkyl;
wherein R 1 is NR 2 R 3 , NR 2 S(═O) 2 R 3 or R 2 OR 3 ;
R 2 and R 3 are independently selected from H, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 6 H 5 OR 4 , and wherein R 2 and R 3 are not both H,
R 4 is C 1 -C 10 alkyl, C 1 -C 10 alkoxy, carbonyl, or amide; and
B is at least one bisphosphonate optionally substituted with OH, halogen, CH 3 , NH 2 ,
or a pharmaceutically acceptable salt thereof.
2. A compound comprising one or more stereoisomers of the formula:
wherein:
′R is H, CH 3 , alkyl, halogen, CF 3 , CN, OH, OCH 3 , or O-alkyl;
n is 1-9;
m is 0-7; and
X is H, OH, halogen, CH 3 , NH 2 , N-alkyl, or N-dialkyl;
or a pharmaceutically acceptable salt.
3. The compound according to claim 2 , wherein n is 1-3, m is 0, and X is H.
4. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
5. The compound according to according to claim 2 , wherein the one or more stereoisomers comprise any one or more of the formula: